| Similar Articles |
|---|
 |
The Motley Fool
April 20, 2004
Brian Gorman |
PPD's New Possibilities The royalty stream from dapoxetine could significantly boost earnings.   |
The Motley Fool
April 18, 2006
Brian Gorman |
PPD Develops Solid Growth The contract research firm cashes in on its core business. Investors celebrated Pharmaceutical Product Development's latest earnings release today by sending the stock up more than 9% in recent trading. |
The Motley Fool
July 15, 2004
Brian Gorman |
Research Company's Stock Surges PPD's (formerly Pharmaceutical Product Development) second-quarter report isn't perfect, but long-term indicators look solid. The stock has risen as much as 14%. |
The Motley Fool
October 18, 2005
Brian Gorman |
PPD's Robust Pipeline The provider of drug development services continues to be a strong performer in its core business even as it demonstrates savvy in its new drug-partnering initiative. Investors, take note. |
The Motley Fool
October 17, 2006
Brian Gorman |
PPD Disappoints? Not Quite Its discovery sciences business hindered results, but PPD remains a winner for investors. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
The Motley Fool
October 26, 2004
Charly Travers |
Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
Bio-IT World
August 2005
G. Steven Burrill |
Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market. |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
Bio-IT World
May 2006
G. Steven Burrill |
Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
April 27, 2010
Brian Orelli |
Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
Bio-IT World
September 16, 2004
Paul King |
Growing Gains When it comes to information technology requirements, the biotech industry is unlike any other. A key enabler of efficient and effective growth is the adoption of IT strategies specific to each of four key stages. |
The Motley Fool
July 6, 2004
Brian Gorman |
Hidden Drug Costs Regulatory requirements play an important role in drug expenses. |
The Motley Fool
July 12, 2004
Brian Gorman |
India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
November 30, 2004
Charly Travers |
Picking Biotech's Winners Doing well as a biotech investor comes as much from avoiding the losers as picking the winners. A quick screen for making winning investment picks. |
The Motley Fool
October 3, 2011
Brian D. Pacampara |
Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion. |
The Motley Fool
May 10, 2006
Brian Gorman |
Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now. |
Bio-IT World
February 2006
G. Steven Burrill |
Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006... |
The Motley Fool
July 1, 2004
Brian Gorman |
Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services. |
The Motley Fool
August 18, 2008
Zoe Van Schyndel |
Funds for a Sick Economy? The biotech sector has been a sleeper with positive returns. Take a look at two biotech mutual funds that are performance leaders. |
The Motley Fool
March 28, 2005
Brian Gorman |
A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities. |
